No Data
No Data
Haite Biotech (300683.SZ) announced first-quarter results with a net loss of 165.455 million yuan, an increase of 1024%
Haite Biotech (300683.SZ) released its report for the first quarter of 2024. The company's revenue was 1.32...
Haite Biotech (300683.SZ) subsidiary HKG-320 injection clinical trial approved
Haite Biotech (300683.SZ) announced that its subsidiary, Wuhan Haite Biotech Innovative Pharmaceutical Research Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HKG-320 injections approved and issued by the State Drug Administration. HKG-320 injection is a potassium ion competitive acid blocker that can reversibly inhibit proton pump secretion function by competing with potassium ions on proton pumps (resting pumps and active pumps). Clinically intended to reduce bleeding after endoscopic treatment of upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcers in adults risk.
Express News | Haite Biotech: Subsidiary Receives Drug Clinical Trial Approval Notice
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
Haite Biotech (300683.SZ): Will consider carrying out CPT clinical trials overseas in due course and seek listing
Gelonghui March 20 丨 Some investors asked Haite Biotech (300683.SZ) on the investor interactive platform, “Please ask when the CPT overseas project will begin.” The company replied that the company will consider carrying out CPT overseas clinical trials in due course and seek listing.
Haite Biotech (300683.SZ) recently received a government subsidy of 52.4 million yuan
Haite Biotech (300683.SZ) announced that the company and its wholly-owned subsidiary Hanrui Pharmaceutical (Jingmen) Co., Ltd...
No Data